

526185

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



26 FEB 2005



(43) International Publication Date
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number
WO 2004/030613 A2

(51) International Patent Classification⁷: **A61K**
(21) International Application Number:
PCT/US2003/027975

(22) International Filing Date:
4 September 2003 (04.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/408,126 4 September 2002 (04.09.2002) US

(71) Applicant (for US only): **UNIVERSITY OF
LOUISVILLE RESEARCH FOUNDATION, INC.**
[US/US]; 2305 Third Street, Louisville, KY 40208 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **ROSS, Gordon, D.**
[US/US]; 11739 Paramount Way, Prospect, KY 40059 (US).

(74) Agents: **CARROLL, Alice, O.** et al.; Hamilton, Brook,
Smith & Reynolds, P.C., 530 Virginia Road, P.O. Box 9133,
Concord, MA 01742-9133 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **CANCER THERAPY USING BETA GLUCAN AND ANTIBODIES**

(57) Abstract: The present invention relates to methods of using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble Beta (1,3; 1,6) glucan (NSG) enhances the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. The glucan does not stimulate the induction of inflammatory cytokines. Also described are methods of using whole glucan particles (WGP) as an immunomodulator by inducing a shift from a Th2 response to the Th1 response, leading to an enhanced antitumor cytotoxic T-cell response.



WO 2004/030613 A2